Hepatitis E: What’s New?
Treatment of HEV Acute HEV Significant improvement of liver functions Retrospective study in France Acute HEV G-3/ 4 (n=21)received RBV monotherapy for median 26 days IS therapy /chemotherapy was suspended in 6 patients All patients cleared HEV within 6 weeks median time to viral clearance of 29 days 2 patients died from liver failure(underlying CLD) Péron JM, et al. Liver Int 2016; 36:328.
Treatment of HEV Chronic HEV Reduction of Immunosuppressive Therapy Antiviral Therapy(RBV) G3 & G4 Eradicate HEV-RNA & achieving SVR SVR: absence of HEV-RNA 12 weeks after cessation of treatment SVR predictor: HEV-RNA 1 st week after therapy/Total lymphocyte count
- Page 2 and 3: HEPATITIS E: WHAT’S NEW? Naglaa Z
- Page 4 and 5: Known Facts: HEV ■ 20 million HEV
- Page 6 and 7: Geographical Distribution of HEV Eg
- Page 8 and 9: HEV Genotypes Four genotypes/24 sub
- Page 10 and 11: Modes of HEV Transmission Fecal-ora
- Page 12 and 13: Clinical Picture of HEV
- Page 14 and 15: Complications of Acute HEV Acute Li
- Page 16 and 17: Clinical Picture: Complications Acu
- Page 18 and 19: Chronic Hepatitis E Persistently el
- Page 20 and 21: Chronic Hepatitis E Other Immunosup
- Page 22 and 23: Diagnostic tests for HEV IgM anti-H
- Page 24 and 25: HEV Diagnosis Acute HEV Chronic HEV
- Page 28 and 29: Treatment of Chronic HEV Reduction
- Page 30 and 31: Response to Antiviral Therapy Stool
- Page 34 and 35: Treatment of HEV: Future Therapy
- Page 36 and 37: Randomized trial in China, 112,604
Treatment of HEV<br />
Acute HEV<br />
Significant improvement of liver functions<br />
Retrospective study in France<br />
Acute HEV G-3/ 4 (n=21)received RBV monotherapy for median 26 days<br />
IS therapy /chemotherapy was suspended in 6 patients<br />
All patients cleared HEV within 6 weeks<br />
median time to viral clearance of 29 days<br />
2 patients died from liver failure(underlying CLD)<br />
Péron JM, et al. Liver Int 2016; 36:328.
Change language